资讯
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...
Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...
ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM. The recent release of the “Genitourinary Syndrome of Menopause: AUA/SUFU [Society of ...
CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...
The study was published in JCO Oncology Practice. “I think 1 thing that people might hypothesize is that the lower citation rates of women-women papers may be due to less female physicians in these ...
Robotic prostate surgery and resource use: When prostate surgery is performed robotically, the patient typically requires a catheter for about 1 week. This leads to increased resource utilization, ...
The AI tool outperformed MRI in assessing for SVI. Unfold AI, an artificial intelligence (AI)-based risk mapping tool, was able to accurately predict seminal vesicle invasion (SVI) in patients with ...
Panelists discuss how evaluating a renal mass requires considering multiple factors, including patient expectations, comorbidities, life expectancy, tumor characteristics such as size and enhancement ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果